iridex corporation, founded in 1989, is a worldwide leader in developing, manufacturing, and marketing innovative and versatile light-based medical systems and delivery devices. we offer laser based solutions for multiple specialties including aesthetic medicine, ophthalmology, and otolaryngology. we also maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. with superior technology for superior results, iridex is dedicated to standards of excellence that meet your own.
Company profile
Ticker
IRIX
Exchange
Website
CEO
David I. Bruce
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
SEC CIK
Corporate docs
IRS number
770210467
IRIX stock data
Latest filings (excl ownership)
8-K
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
26 Mar 24
8-K
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
28 Nov 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
8-K
Iridex Reports Third Quarter 2023 Financial Results and Business Update
14 Nov 23
8-K
In the Court of Chancery of the State of Delaware
7 Nov 23
8-K
Other Events
31 Oct 23
8-K
In the Court of Chancery of the State of Delaware
18 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Iridex Reports Second Quarter 2023 Financial Results
10 Aug 23
Transcripts
IRIX
Earnings call transcript
2023 Q4
26 Mar 24
IRIX
Earnings call transcript
2023 Q3
14 Nov 23
IRIX
Earnings call transcript
2023 Q2
10 Aug 23
IRIX
Earnings call transcript
2023 Q1
11 May 23
IRIX
Earnings call transcript
2022 Q4
9 Mar 23
IRIX
Earnings call transcript
2022 Q3
11 Nov 22
IRIX
Earnings call transcript
2022 Q2
15 Aug 22
IRIX
Earnings call transcript
2022 Q1
13 May 22
IRIX
Earnings call transcript
2021 Q4
11 Mar 22
IRIX
Earnings call transcript
2021 Q3
12 Nov 21
Latest ownership filings
4
Patrick Mercer
21 Sep 23
4
Scott Shuda
15 Jun 23
4
KEN LUDLUM
15 Jun 23
4
Robert Earle Grove
15 Jun 23
4
BEVERLY A HUSS
15 Jun 23
4
Nandini Devi
15 Jun 23
SC 13D
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
23 Nov 22
4
David Bruce
31 Oct 22
4
Patrick Mercer
31 Oct 22
4
Patrick Mercer
3 Oct 22
Financial summary
Quarter (USD) | Sep 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Jan 22 | Jan 21 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.98 mm | 7.98 mm | 7.98 mm | 7.98 mm | 7.98 mm | 7.98 mm |
Cash burn (monthly) | 613.33 k | 656.25 k | 582.00 k | 699.50 k | 594.00 k | 613.00 k |
Cash used (since last report) | 3.66 mm | 3.92 mm | 3.47 mm | 4.18 mm | 3.55 mm | 3.66 mm |
Cash remaining | 4.32 mm | 4.06 mm | 4.51 mm | 3.81 mm | 4.44 mm | 4.32 mm |
Runway (months of cash) | 7.0 | 6.2 | 7.7 | 5.4 | 7.5 | 7.1 |
Institutional ownership, Q2 2023
51.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 1 |
Closed positions | 4 |
Increased positions | 6 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 7.27 bn |
Total shares | 8.38 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Topcon America | 1.62 mm | $11.81 mm |
Paragon Associates & Paragon Associates Ii Joint Venture | 1.00 mm | $2.17 bn |
Roland Brent Alexander | 882.00 k | $2.32 mm |
North Tide Capital | 760.07 k | $1.91 mm |
Wyers Point Master | 744.30 k | $1.27 mm |
Vanguard | 557.20 k | $1.21 bn |
BlueLine Capital Partners | 493.67 k | $3.79 mm |
Renaissance Technologies | 419.16 k | $910.00 k |
Isthmus Partners | 391.13 k | $848.76 mm |
AMH Equity | 330.82 k | $717.88 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Sep 23 | Patrick Mercer | Stock Option Common Stock | Grant | Acquire A | No | No | 2.13 | 115,000 | 244.95 k | 115,000 |
14 Jun 23 | Ludlum Ken | Common Stock | Grant | Acquire A | No | No | 1.91 | 39,267 | 75.00 k | 101,711 |
14 Jun 23 | Shuda Scott | Common Stock | Grant | Acquire A | No | No | 1.91 | 39,267 | 75.00 k | 108,066 |
14 Jun 23 | Beverly A Huss | Common Stock | Grant | Acquire A | No | No | 1.91 | 39,267 | 75.00 k | 66,739 |
14 Jun 23 | Nandini Devi | Common Stock | Grant | Acquire A | No | No | 1.91 | 39,267 | 75.00 k | 77,159 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
28 Mar 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
26 Mar 24
Iridex: Q4 Earnings Insights
26 Mar 24
Iridex Q4 2023 GAAP EPS $(0.18) Misses $(0.05) Estimate, Sales $12.458M Miss $14.900M Estimate
26 Mar 24
Earnings Scheduled For March 26, 2024
26 Mar 24
Press releases
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
26 Mar 24
Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024
20 Mar 24
Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
11 Jan 24